Cardiovascular Research Active Trials

  • aMAZE Trial (Alternative-MAZE procedure)
  • ATTAIN (Stability Quad Trial)
  • ENABLE MRI (Expanding MRI Access for Patients with New and Existing ICDs and CRT-Ds) 
  • SURESCAN - Closed to Enrollment
  • SYMPLICITY
  • PSR (Product Surveillance Registry)
  • CAMELLIA STUDY
    • Sponsor is Eisai
    • closed to enrollment, patients are in follow up phase
    • double blind study with FDA approved locaserin (Belviq) assessing long-term effects on theincidence of heart attacks, stroke and development of Type II Diabetes in overweight individuals with a history of heart disease or those with multiple risk factors for heart disease.
    • enrollment 12,000 worldwide, 28 at this site
    • expected to last approximately 5 years
    • patients return every 3-4 months for study visits and lab work with the research staff.
  • GLORIA AF
    • Sponsor is Boehringer Ingelheim
    • closed to enrollment, patients are in follow up phase for 3 years
    • registry for people with newly diagnosed atrial fibrillation not caused by a heart valve problem
    • looks at how doctors decide what medications are used to treat atrial fibrillation to reduce complications such as stroke.
    • patients return every 6-12 months with the research staff for 3 years.
  • WRAP IT - Closed to Enrollment
    • Sponsor is Medtronic
    • Closed to enrollment
    • Randomized, single blind study looking to compare the rate of infections through 12 months post pacemaker/defibrillator generator change.Some participants receive an FDA approved dissolvable pouch with an antibiotic.
    • follow up is the same as usual pacemaker/defibrillator care.
  • AMARIN/REDUCE IT
    • Sponsor is AMARIN Pharmaceuticals
    • closed to enrollment
    • Randomized, double blind study using the FDA approved drug Vascepa® (icosapent ethyl) for patients with very high levels of triglycerides.
    • patients follow up either by phone or yearly for visits with the research staff
  • BeAT HF